



## Coronavirus and Different Vaccines

*Vaishnavi Hamand, Shital sable, Fardeen Jinturkar ,Sumer Sayyad*

SVP College of pharmacy India

### Abstract:

In all over the world coronavirus are spread and this virus is affected on human body through the respiratory track. So many Nations are introduced their vaccines for coronavirus. Like vaccine are Covaxin Vaccine(Bharat Biotech), Covishild vaccine(Serum institute of India),Moderna Vaccine(NIAID), Sputnik v Vaccine (Gamaleya Research Institute), Pfizer Vaccine (the pfizer Biotech) etc. The vaccine having the particular efficiency power of different different vaccines. In their preparation and developing vaccine to protect against covid19. As a result, they have developed different types of vaccine including . Recombinant proteins subunit vaccine, replication incompetent vector vaccine, Nucleic acid vaccines. In the vaccine viruses are in inactive forms or dead form of the virus, so that's can not cause an infection because they do not contain live virus. and some vaccine are Nucleic acid vaccine also called as m-RNA based vaccine. Each of these vaccine is manufactured and prepared to target of particular pathogens.

**Keywords:** Vaccines, coronavirus, covishild, moderna vaccine, Sputnik v, pfizer, mRNA, Nucleic acid, pathogens.

### 1 Introduction:

Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). A novel coronavirus (COVID-19) was identified in 2019 in Wuhan, China. The COVID-19 vaccine introduction toolkit equips all countries to prepare for and implement COVID-19 vaccination by providing guidance, tools, and training. This toolkit is intended to support Ministries of Health, health workers, partner organizations, and other stakeholders.

In the world having many vaccine Like vaccine are Covaxin Vaccine(Bharat Biotech), Covishild vaccine(Serum institute of India),Moderna Vaccine(NIAID), Sputnik v Vaccine (Gamaleya Research Institute), Pfizer Vaccine (the pfizer Biotech) etc. And corona vaccine having two doses in which 1st dose made antibody against covid and second dose is boost immunization.



The age group of covaxin been approved for 12year and above. covishild Has been approved for 18year and above. And also sputink v has been give 18 and above. Covaxin is prepared on a tried and tested platform of dead Viruse. Covishild has been prepared using the viral vectors platform.

Corona vaccine is showing some Side effects to COVID-19 vaccines have mostly Been mild to moderate and short-lasting. Include:fever,fatigue,headache,muscle Pain,diarrhoea,pain at the injection site,The chances of any of these side effects Following vaccination differ according to the specific COVID-19 vaccine.More Serious or long-lasting side effects to vaccines are possible but extremely rare. Vaccines are continually monitored to detect rare adverse events. The new variant of corona virus is in found in uk they have scientific name is B1.1.7 and this virus also WHO give a name is Alfa varients found in September 2020, and those Viruse variant found in South Africa they variant have scientific Name is B1.351 and WHO give the name is Beta variant found in may 2020 and Virus variant found in Brazil so scientists give the name P1 and WHO give the Name is Gamma variant found in November 2020 and those varients found in India the scientific name is B1.617.2 and WHO give name is Delta variant found in October 2020.

Human body is made the Antibody against the coronavirus variant and bodys Adaptive immune system can learn to recognise new invading pathogens such as Coronavirus SARS-CoV-2.

## 2 Mechanism:

Corona vaccine is affectes on against the codiv19 variant. Different vaccines having different mechanisms of action is discussed below.

### a) SPUTNIK-V

Sputnik v vaccine is a heterologous prime Boost vaccination, which is in simple term that means, using two different vectors, of two dose of vaccinations. Sputnik v, vaccine is a adenovirus viral vector type vaccine. It uses two two different humans as a vector that is adenovirus vector. This vaccine developed by GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY ., in Russian .

**EFFICACY** : sputnik – V vaccine shows efficacy of 91.6% as report resource present on Lancet.

**Dose** : Sputnik V is administered in two dose (21days apart).

1<sup>st</sup> dose efficacy is arranges in between 70-80%

2<sup>nd</sup> dose efficacy of sputnik v vaccine is 91.6%.





That means SPUTNIK-V vaccine quite promising in after first dose only. That's why some countries have gone for single dose only. Therefore that sputnik v vaccine is a light vaccine.

### NEW NAMES FOR COVID-19 VARIANTS



#### Variants of concern

WHO label	Pango lineage	Earliest documented samples
Alpha	B117	United Kingdom Sep 2020
Beta	B1351	South Africa May 2020
Gamma	P1	Brazil Nov 2020
Delta	B16172	India Oct 2020

Country/region	Scientific name	WHO name
 Kent, UK	B.1.1.7	Alpha
 South Africa	B.1.351	Beta
 Brazil	P.1	Gamma
 India	B.1.617.2	Delta

Source: WHO

### Type of Vaccines :

Adenovirus viral vector type Vaccine: Which incorporate DNA 8! And the only genetic material in the form of dsDNA it use recommended Human adenovirus and in this type of vaccine we use two types of Adenovirus.

1.Type-26 or Serotype26 (rAD-26)


2.Type- 5 Adenovirus (rAd-5)

Type 26 rAd26 is used as vector in 1<sup>st</sup> dose and Type 5 rAd5 is used as a vector in 2<sup>nd</sup> dose in a administration, That's why these termed know as HETEROLOGOUS PRIME BOOST As it used two different vectors for a same antigens. Both vectors carry genes for SARS-COV2 Glycoprotein-S (s protein).

### 3 Mechanism of Heterologous prime Boost vaccination.

The Sputnik V (Gam-COVID-Vac) is based on safe and effective human adenovirus vector platform using two different adenoviral vectors - Adenovirus 26 (Ad26) and Adenovirus 5 (Ad5) as an expression of SARS-CoV-2 spike protein gene.

The use of two varying serotypes is a unique approach that provide long-lasting immunity and allows to boost the immune response. The carrier viruses are modified and cannot begin a productive infection; they enter cells, express the spike protein, and then stop. High sensitivity recorded that a few adenovirus genes were expressed, although at very low level.



Eventually, the vaccine-infected cells are destroyed by the very immunity they are designed to evoke. Recombinant adenoviruses (rAD) have been used widely as vaccine vectors due to their quality to accommodate large genetic payloads and, although unable to replicate, they trigger the intuitive immunity sensors sufficiently to make sure a robust immune system in nature.

A heterologous recombinant adenovirus approach is shared with the chimpanzee adenovirus (ChAdOx) vectored COVID-19 vaccine Oxford/AstraZeneca, Adenovirus 26 (Ad26) vectored COVID-19 vaccine by the Johnson & Johnson, and the Adenovirus 5 (Ad5) vectored COVID-19 vaccine by CanSinoBIO-Beijing Institute of Biotechnology.

#### b) Mechanism of Covishield Vaccine:

The vaccine has been shown to be more beneficial for you than other drugs. After applying Covishield Vaccine, your body kills the corona inside the body through its immunity. The Covishield vaccine protects your body from contracting it instead of eliminating the virus. The Covishield vaccine is currently being used in India. According to the citizens who have been given this vaccine, now their body is more capable of fighting diseases than before. As soon as the vaccine is introduced, the body acts as a shield to fight the coronavirus. The vaccine checks the coronavirus and prevents it from entering the body. If the virus penetrates into the body, the vaccine creates antibodies and exits the body.

#### c) Covaxin Vaccine

COVAXIN is an inactivated vaccine obtained from the SARS-CoV-2 strain isolated at the NIV, Pune, an Indian virology re-

search institute. The vaccine is used along with immune stimulants, commonly known as vaccine adjuvants (Alhydroxiqum-II), to improve immune response and longer-lasting immunity. The vaccine candidate is produced through the formulation of the inactivated virus with Kansas-based Viro-Vax's Alhydroxiqum-II adjuvant. COVAXIN mainly contains 6µg of whole-virion inactivated SARS-CoV-2 antigen (Strain: NIV-2020-770), and the other inactive components such as 250µg aluminium hydroxide gel, 15µg TLR 7 / 8 agonist (imidazoquinolone), 2.5mg TM 2-phenoxyethanol, and phosphate buffer saline up to 0.5ml. The vaccine requires no sub-zero storage and reconstitution requirement and available for use in multi-dose vials, stable at 2-8°C.

---

#### 4 Conclusion:

Science, research and vaccine development have been the reason of hope in the ongoing Covid-19 pandemic. Vaccine research and development globally has made a giant leap forward and the availability of many vaccines has raised the hope that we will win against the virus and the disease soon. In the end, when vaccines are licensed after clinical trial and review of data — no matter the platform on which they are developed — all serve a common purpose: to protect the vaccinated individual from the deadly disease coronavirus is affected on human lungs so that why covid vaccine are create in antibody and that's why, human immune system are strong and make multiple copies and efficacy power of vaccine are important .

---

#### Reference:

1. XC, Agnihotram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. *Proc Natl Acad Sci USA*. 2014;111(19):E2018-2026.
2. Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, Zhang B, Yuen KY, Perlman S, Gao GF, Yan J. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. *Cell Res*. 2015;25(11):1237-49.
3. Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. *Viral Immunol*. 2013;26(2):126-32.
4. W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. *J Virol*. 2017.
5. NCBI-Reference-Sequence. SARS coronavirus Tor2, complete genome. 2020.
6. NCBI-Reference-Sequence. Middle East respiratory syndrome-related coronavirus isolate HCoV-EMC/2012, complete genome. 2020.
7. Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. *Front Microbiol*. 2020;11:298.
8. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. *Virology*. 2010;7:299.
9. Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R, Zhou D, Dai E, Wang X, Si B, Song Y, Li J, Yang L, Wang J, Wang H, Pang X, Zhai J, Du Z, Liu Y, Zhang Y, Li L, Wang J, Sun B, Yang R. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. *Microbes Infect*. 2005;7(5-6):882-9.
10. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci USA*. 2004;101(26):9804-9.
11. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. *J Virol*. 2014;88(15):8597-614.
12. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochem Biophys Res Commun*. 2004;324(2):773-81.
13. Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from *Escherichia coli* as booster induces high titer of neutralizing antibody against SARS coronavirus. *Vaccine*. 2005;23(42):4959-68.
14. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kravnyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DB. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. *Sci Transl Med*. 2015;7(301):301ra132.
15. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. *J Virol*. 2005;79(5):2678-88.
16. Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. *J Virol*. 2004;78(22):12672-6.

17. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. *Vaccine*. 2014;32(45):5975–82.
18. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford CVTG. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):467–78.